Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03609814 · ClinicalTrials.gov registry record
Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 30
- Enrollment target
NCT03609814: Completed study, sponsored by University of California, San Francisco.
NCT03609814 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03609814 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Fludarabine and clofarabine are chemotherapy drugs used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of clofarabine and fludarabine in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that clinical and individual factors cause changes in clofarabine and fludarabine drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.
Interventions
- DRUG Fludarabine Injection
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-01-26 |
| Est. Completion | 2020-06-30 |
What the finished NCT03609814 record still lists
NCT03609814 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Fludarabine Injection is the first listed.
NCT03609814 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03609814 about?
NCT03609814 is a clinical study titled "Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)". Fludarabine and clofarabine are chemotherapy drugs used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of clofarabine and fludarabine in their bodies and if drug levels are related to whether or not a...
What is the current status of trial NCT03609814?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2016-01-26. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03609814?
The interventions under investigation include: Fludarabine Injection (DRUG), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT03609814?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI